European Antitrust Investigations Boosted As AstraZeneca Challenge Fails
This article was originally published in The Pink Sheet Daily
The Court of Justice of the European Union decision to uphold a €52.5 million ($67.7 million) fine against AstraZeneca for hindering generic competition will encourage the executive Commission to pursue potentially abusive pay-for-delay practices.
You may also be interested in...
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
The European Court of Justice sides with the European Commission: manipulating the patent and regulatory systems to block competitors gets AZ a slap on the wrist and serves as a warning to others.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.